top of page
Browse by category
Search
FDA approves Tonix’ Phase 2 Trial of TNX-2900 for Prader-Willi Syndrome
The FDA has cleared Tonix Pharmaceuticals’ Investigational New Drug (IND) application to support clinical development of TNX-2900...
Aardvark Therapeutics gains Rare Pediatric Disease Designation for Prader-Willi Syndrome
The FDA has granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare...
MBS provides safe and rapid weight loss for patients with Prader-Willi Syndrome
The current data on metabolic and bariatric surgery (MBS) in patients with Prader-Willi Syndrome (PWS) reveal that laparoscopic sleeve...
Journal Watch 17/08/2022
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Three trials to assess ARD-101 including for refractory weight gain post-bariatric surgery
Enrolment has begun in three Phase 2 studies of ARD-101, a first-in-class small molecule bitter taste receptor (TAS2R) pan-agonist. Two...
Browse by tag
bottom of page